bei 18,822,553 Mio. Stück.
Hm... Unglaublich. Jämmerlich ist es, wenn man den Wert auf der Watshliste hat und ein Tag nicht aufpasst.
Na gut, Wunder gibt es immer wieder...
Der Auslöser war wohl die folgende Nachricht:
CARDIMA INC Quick Quote: CRDM 0.25
Emerging Stock Report: Fighting a Killer
5/25/2006
May 25, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Since 1900 CVD Cardio vascular disease has been the No. 1 killer in the United States every year but 1918. Nearly 2,500 Americans die of CVD each day, an average of one death every 35 seconds. CVD claims more lives each year than the next four leading causes of death combined, which are cancer, chronic lower respiratory diseases, accidents, and diabetes mellitus.
The Emerging Stock Report is initiating coverage on Cardima, Inc. (OTCBB: CRDM). The company announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) marketing clearance for the new Cardima Ablation System, which ablates (Ablation is defined as the removal of material from the surface of an object by vaporization, chipping, or other erosive processes) cardiac tissue during heart surgery using radio frequency (RF) energy. This system is expected to be used primarily by surgeons performing cardiac surgery using standard hospital laparoscopic as well as thorascopic techniques.
The Cardima Ablation System uses three components: commercially available surgical radio frequency generators; the new Cardima Surgical Ablation Probe with a linear array of multi-electrodes and adjacent thermocouples using the core technology similar to the Company's REVELATION(R) series ablation micro-catheters; and a novel energy management device called the INTELLITEMP(R), which uses a temperature feedback feature to apply RF energy to single or multiple electrodes on the probe simultaneously. The new surgical ablation probe includes a specially designed stabilizer suction device with an illuminated tip for better visibility, which is clipped to the electrode array to maintain electrode-tissue contact during hands free ablation.
Cardima was incorporation in November 1992, it has developed, produced and sold a variety of micro-catheters designed for the diagnosis and treatment of the two most common forms of cardiac arrhythmias: atrial fibrillation (AF) (Atrial Fibrillation (AF) is a cardiac rhythm disorder caused by chaotic electrical impulses within the heart. It is a fast, irregular heartbeat originating in the atria. The heart is divided into four chambers, the upper two are the atria, and the lower two chambers are the ventricles) and ventricular tachycardia (VT). Since 2001 the company's efforts have focused on developing differentiated products that diagnose and treat AF, including our REVELATION(R) TX micro-catheter for use in the Electrophysiology (EP) market, and our Surgical Ablation System (SAS) for use in the surgical market.
The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.
Get a Complimentary Subscription at www.emergingstockreport.com
Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.
Safe Harbor
All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.
ESR's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements
CONTACT: e-mail: ian@emergingstockreport.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
Hm... Unglaublich. Jämmerlich ist es, wenn man den Wert auf der Watshliste hat und ein Tag nicht aufpasst.
Na gut, Wunder gibt es immer wieder...
Der Auslöser war wohl die folgende Nachricht:
CARDIMA INC Quick Quote: CRDM 0.25
Emerging Stock Report: Fighting a Killer
5/25/2006
May 25, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Since 1900 CVD Cardio vascular disease has been the No. 1 killer in the United States every year but 1918. Nearly 2,500 Americans die of CVD each day, an average of one death every 35 seconds. CVD claims more lives each year than the next four leading causes of death combined, which are cancer, chronic lower respiratory diseases, accidents, and diabetes mellitus.
The Emerging Stock Report is initiating coverage on Cardima, Inc. (OTCBB: CRDM). The company announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) marketing clearance for the new Cardima Ablation System, which ablates (Ablation is defined as the removal of material from the surface of an object by vaporization, chipping, or other erosive processes) cardiac tissue during heart surgery using radio frequency (RF) energy. This system is expected to be used primarily by surgeons performing cardiac surgery using standard hospital laparoscopic as well as thorascopic techniques.
The Cardima Ablation System uses three components: commercially available surgical radio frequency generators; the new Cardima Surgical Ablation Probe with a linear array of multi-electrodes and adjacent thermocouples using the core technology similar to the Company's REVELATION(R) series ablation micro-catheters; and a novel energy management device called the INTELLITEMP(R), which uses a temperature feedback feature to apply RF energy to single or multiple electrodes on the probe simultaneously. The new surgical ablation probe includes a specially designed stabilizer suction device with an illuminated tip for better visibility, which is clipped to the electrode array to maintain electrode-tissue contact during hands free ablation.
Cardima was incorporation in November 1992, it has developed, produced and sold a variety of micro-catheters designed for the diagnosis and treatment of the two most common forms of cardiac arrhythmias: atrial fibrillation (AF) (Atrial Fibrillation (AF) is a cardiac rhythm disorder caused by chaotic electrical impulses within the heart. It is a fast, irregular heartbeat originating in the atria. The heart is divided into four chambers, the upper two are the atria, and the lower two chambers are the ventricles) and ventricular tachycardia (VT). Since 2001 the company's efforts have focused on developing differentiated products that diagnose and treat AF, including our REVELATION(R) TX micro-catheter for use in the Electrophysiology (EP) market, and our Surgical Ablation System (SAS) for use in the surgical market.
The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.
Get a Complimentary Subscription at www.emergingstockreport.com
Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.
Safe Harbor
All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.
ESR's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements
CONTACT: e-mail: ian@emergingstockreport.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
